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Abstract
Background: Prostate carcinoma is among the most common solid tumors to secondarily involve the male breast.
Prostate specific antigen (PSA) and prostate-specific acid phosphatase (PSAP) are expressed in benign and
malignant prostatic tissue, and immunohistochemical staining for these markers is often used to confirm the
prostatic origin of metastatic carcinoma. PSA expression has been reported in male and female breast carcinoma
and in gynecomastia, raising concerns about the utility of PSA for differentiating prostate carcinoma metastasis to
the male breast from primary breast carcinoma. This study examined the frequency of PSA, PSAP, and hormone
receptor expression in male breast carcinoma (MBC), female breast carcinoma (FBC), and gynecomastia.
Methods: Immunohistochemical staining for PSA, PSAP, AR, ER, and PR was performed on tissue microarrays
representing six cases of gynecomastia, thirty MBC, and fifty-six FBC.
Results: PSA was positive in two of fifty-six FBC (3.7%), focally positive in one of thirty MBC (3.3%), and negative in
the five examined cases of gynecomastia. PSAP expression was absent in MBC, FBC, and gynecomastia. Hormone
receptor expression was similar in males and females (AR 74.1% in MBC vs. 67.9% in FBC, p = 0.62; ER 85.2% vs.
68.5%, p = 0.18; and PR 51.9% vs. 48.2%, p = 0.82).
Conclusions: PSA and PSAP are useful markers to distinguish primary breast carcinoma from prostate carcinoma
metastatic to the male breast. Although PSA expression appeared to correlate with hormone receptor expression,
the incidence of PSA expression in our population was too low to draw significant conclusions about an
association between PSA expression and hormone receptor status in breast lesions.
Introduction
Primary carcinoma of the male breast accounts for less
than 1% of cancers in men [1,2]. Uncommonly, meta-
static malignancies may also involve the male breast
[1,3].
Extramammary malignancies metastatic to the breast
reportedly represent 0.46 - 5% of all malignant breast
fine needle aspiration biopsies in females and males [4].
Incidence rates of metastasis to the breast as high as
6.6% have been reported when hematologic malignan-
cies are included [5]. Prostatic carcinoma is among the
most commonly reported solid tumors to secondarily
involve the male breast [2]. In one study, 26% of
p a t i e n t sw i t hak n o w nh i s t o r yo fp r o s t a t ec a r c i n o m a
were found to have metastases to the breast at autopsy
[6].
Metastatic neoplasms to the breast generally occur in
the setting of disseminated metastatic disease, however
patients may present with a breast mass as the first
manifestation of metastatic cancer [4]. Metastatic malig-
nancies involving the breast are associated with a poor
prognosis, with the majority of patients dying within
one year of diagnosis [7-9]. Treatment generally involves
systemic chemotherapy, and correct diagnosis is essen-
tial to provide accurate prognostic information and pre-
vent unnecessary surgery in these patients.
Reports of prostate specific antigen (PSA) expression
in male and female breast carcinomas [3,10-15] have
raised questions about the value of PSA staining in dif-
ferentiating metastatic prostatic carcinoma from primary
breast carcinoma. PSA expression has been reported to
correlate with expression of androgen receptor (AR),
estrogen receptor (ER) and progesterone receptor (PR)
in some studies [10,13], however other studies have
found no correlation [12].
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PSA and prostate specific acid phosphatase (PSAP)
expression in male breast carcinoma (MBC), female
breast carcinoma (FBC) and gynecomastia and to corre-
late these findings with hormone receptor expression.
Methods
A search of electronic medical records from the Emory
University Healthcare system was conducted to identify
cases of MBC, FBC, and gynecomastia. With Institu-
tional Review Board approval from Emory University
(IRB00012568, 517-2002), tissue microarrays (TMAs)
representing six cases of gynecomastia (four 0.1-cm
cores per case), thirty MBC (four cores per case), and
fifty-six FBC (two cores per case) were constructed from
paraffin-embedded tissue blocks of surgical specimens.
Immunohistochemistry
Immunohistochemical staining for PSA, PSAP and AR,
ER, and PR were performed on 5-micron sections from
TMA blocks. Antibody clones and dilutions are listed in
Table 1. Sections are tested for the presence of primary
antibody using the Dako Envision+dual link system
which is an horseradish peroxidase labeled polymer
(Dako, Carpinteria, CA) with heat-induced antigen
retrieval.
The sections were deparaffinized and rehydrated in
deionized water. Antigen retrieval was in heated citrate
buffer (pH 6.0), using an electric pressure cooker for
3 minutes at 12-15 pounds per square inch (approxi-
mately 120°C); slides were cooled for 10 minutes prior
to immunostaining.
The slides were loaded on the Dako AutoStainer Plus
(Dako) and exposed to 3% hydrogen peroxide for five
minutes, incubated at room temperature with primary
antibody for 30 minutes, followed by labeled polymer
(Envision+dual link) for thirty minutes, 3,3’-diamino-
benzidine as a chromogen for five minutes, and hema-
toxylin counterstain for five minutes.
Interpretation
PSA and PSAP were considered positive if any cytoplas-
mic staining was observed. Positive reactions for AR,
ER, and PR were defined by nuclear staining observed in
at least 10% of tumor cells.
Statistical analysis
P-values for hormone receptor status of FBC and MBC
were determined by Fisher’s exact test.
Results
Immunohistochemical staining results are summarized
in Table 2. PSA was positive in two of 56 FBC (3.7%),
and focally positive (< 1% of cells) in one of 30 MBC
(3.3%). Hormone receptor expression was similar in
males and females (p = 0.62, 0.18, and 0.82 for AR, ER,
and PR, respectively).
Of the two PSA-positive FBC cases, one was positive
for AR, ER, and PR, and the other was negative for AR
(fewer than 10% of nuclei staining), ER and PR (Figure
1). The PSA-positive MBC was positive for AR, ER, and
PR. The number of PSA-positive cases was too small to
draw any significant conclusions about the correlation
between PSA expression and hormone receptor status.
The clinicopathologic features of the PSA-positive
cases are listed in Table 3. One of the three PSA-posi-
tive cases was well-differentiated (histologic grade I),
and the remaining cases were poorly differentiated (his-
tologic grade III).
Discussion
Prostate carcinoma has been reported to be the most
common metastatic malignancy to the male breast [2].
Lung cancer and melanoma are also among the com-
monly reported neoplasms that secondarily involve the
male breast [16]. While the treatment for primary breast
carcinoma involves surgical resection, treatment of
metastatic carcinoma to the breast generally involves
systemic therapy. Thus, accurate diagnosis is essential to
prevent unnecessary surgery and provide optimal treat-
ment and prognostic information to these patients.
Radiographic clues may aid in the differentiation of
primary breast carcinoma from metastatic disease, as
primary lesions tend to be spiculated and metastases are
often more discrete and rounded [4,5,7,8]. Calcifications
are more likely to occur in primary breast carcinomas
Table 1 Antibodies and Interpretation Criteria
Antibody Source Clone Dilution Positive Control Positive Result
PSA Dako Polyclonal 1:10,000 Prostate Any cytoplasmic staining
PSAP Dako PASE/4LJ 1:1,280 Prostate Any cytoplasmic staining
AR Dako F39.4.1 1:40 Prostate Nuclear staining ≥ 10%
ER Dako ID5 1:50 Breast carcinoma Nuclear staining ≥ 10%
PR Dako PgR636 1:400 Breast carcinoma Nuclear staining ≥ 10%
PSA - prostate specific antigen; PSAP - prostate specific acid phosphatase; AR - androgen receptor; ER - estrogen receptor; PR - progesterone receptor.
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and elastosis are more commonly encountered in pri-
mary breast carcinoma than in metastatic tumors.
Nonetheless, metastatic malignancies may closely mimic
primary breast carcinoma in imaging studies and on his-
tologic examination, and definitive diagnosis often
depends on immunohistochemical studies [1].
P S Aa n dP S A Pa r ec o m m o n l yu s e dt os u g g e s tp r o -
static origin of malignant cells. PSA is a 33 kD glycopro-
tein with serine protease activity [11]. The detection of
PSA in tissues by immunohistochemical staining is
widely used to confirm the prostatic origin of carci-
noma. Though initially thought to be specific to the
prostate gland, PSA has been detected in other tissues,
including the parotid, pancreas, and kidney, carcinomas
of the ovary, lung, and breast [15], neuroendocrine cells
[17], and benign breast lesions [11].
PSAP is a tyrosine phosphatase involved in growth
regulation, and is regarded as a less sensitive, more spe-
cific marker of prostatic origin of cells [2]. According to
Erbas et al., PSAP was detected in breast cyst fluid sam-
ples by ELISA; [18] however, immunohistochemically
detectable PSAP expression was not identified in breast
carcinomas or gynecomastia in previous studies
[2,3,12,19].
Immunohistochemical detection of PSA and PSAP has
been useful in the diagnosis of prostate carcinoma
metastasis to the breast. Cheng et al. [3] reported one
such case, and reviewed 33 additional cases from the lit-
erature. PSA expression was identified in 12 of 12 cases
(100%) and PSAP expression in 13 of 14 cases (92.8%)
where immunohistochemistry was performed.
Our series represents the largest group of MBCs to be
tested for immunohistochemically detectable PSA
expression, performed in conjunction with a significant
number of FBCs.
In our population, PSA expression was not detected in
gynecomastia, and was uncommon in both male and
female breast cancers. PSAP expression was not
detected in benign or malignant breast tissue, similar to
previous reports [2,3,12,19].
T a b l e4s u m m a r i z e st h er e s u l t so fp r e v i o u ss t u d i e s
that examined PSA expression in breast lesions. The
reported frequency of PSA-positive breast carcinoma
varies from 0% [3,19,20] to 100% [21]. As similar antibo-
dies were used in many of these studies, the reason for
this discrepancy is not entirely clear, but may be related
to differences in immunohistochemical staining proto-
cols. Of note, Ilvan et al. [10] and Miller et al. [11] used
monoclonal PSA antibodies in their studies, and
reported similar low rates of PSA expression (10.1% and
9% of breast cancer cases, respectively).
The frequency of PSA expression in our series of
breast carcinomas was lower than in a report by Kidwai
et al. (2003), where PSA positivity was observed in six
of 26 cases of MBC (23%) [12]. Although staining for
PSA was focal in five of the positive cases, one case was
diffusely positive. The polyclonal PSA antibody used in
our study was similar to that used by Kidwai et al.
Other studies, most of which focused predominantly on
FBC, have reported results similar to those described by
Kidwai et al. [3,10,13,15,22]
Our results are similar to those reported by Carder et
al. [2] and Gatalica et al., [19] who noted PSA positivity
in one of eleven MBCs (9.1%) and zero of eight MBCs
(0%), respectively. In the latter study, five of eighteen
cases of gynecomastia (27.8%) showed staining for poly-
clonal PSA. When a monoclonal PSA antibody was
used, however, only one case remained positive (5.6%)
[19].
Based on previous reports, PSA expression appears to
be less common in MBC than in FBC. When taken
together, the overall incidence of PSA expression in
breast cancer cases reported in the literature is 28.5%
(215 of 754 total cases; range 0% [3,19,20] to 100%)
[21]. When only MBC is considered, the incidence is
14.5% (9 of 62 cases; range 0% [3,19] to 100%) [21].
When our cases are included, the overall incidence is
26% (218 of 836 cases) and the incidence in MBC is
11% (10 of 92 cases). In contrast to previous studies, the
percentage of PSA-positive FBC cases was similar to the
percentage of PSA-positive MBC cases in our study.
The physiologic significance of PSA expression in
extraprostatic tissues is not known. Though PSA has
been shown to hydrolyze or otherwise modify substrates
such as fibrinogen and laminin [23], its function (if any)
in breast tissue and its prognostic significance in breast
carcinoma remain unclear. Previous reports have sug-
gested a relationship between PSA expression and carci-
nomas of low histologic grade [14,15]. In the current
study, PSA expression did not appear to be associated
with grade. PSA-positive tumors were either well-
Table 2 PSA, PSAP, and Hormone Receptor Expression in
MBC, FBC, and Gynecomastia
Marker Gynecomastia MBC FBC P-value (MBC vs
FBC)
PSA 0/5 (0%) 1/30 (3.3%) 2/54 (3.7%) 1.00
PSAP 0/5 (0%) 0/29 (0%) 0/54 (0%) 1.00
AR 4/5 (80%) 20/27
(74.1%)
38/56
(67.9%)
0.62
ER 6/6 (100%) 23/27
(85.2%)
37/54
(68.5%)
0.18
PR 5/5 (100%) 14/27
(51.9%)
27/56
(48.2%)
0.82
MBC - male breast carcinoma; FBC - female breast carcinoma; PSA - prostate
specific antigen; PSAP - prostate specific acid phosphatase; AR - androgen
receptor; ER - estrogen receptor; PR - progesterone receptor.
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tumors were fairly evenly distributed between histologic
grades I (23%), II (39%), and III (38%) (data not shown).
PSA positivity in breast cancer cells has also been
reported to correlate with hormone receptor positive
status [10] and possibly with improved prognosis [11],
although other studies have found no such association
[12]. PSA expression has been induced by androgens,
progesterone, and glucocorticoids in steroid receptor-
positive breast cancer cell lines [24], suggesting that
PSA expression in breast tumors is indeed under hor-
monal control. In a study of 61 PSA-positive FBC,
Figure 1 Results of immunohistochemical stains in PSA-positive breast carcinomas. DP FBC - Diffusely PSA-positive female breast
carcinoma; FP FBC - Focally PSA-positive female breast carcinoma; MBC - PSA-positive male breast carcinoma; PSA - prostate specific antigen;
PSAP - prostate specific acid phosphatase; AR - androgen receptor; ER - estrogen receptor; PR - progesterone receptor.
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positive, 28 (46%) were ER-positive, and 22 (36%) were
PR-positive [13]. In our study, two of three PSA-positive
carcinomas were positive for AR, ER, and PR, and the
hormone receptor-negative case demonstrated focal
weak AR expression that did not meet our 10% thresh-
old for AR positivity. Our results suggest a correlation
between PSA expression and expression of hormone
receptors, though the incidence of PSA expression in
our population was too low to draw any significant con-
clusions about this association.
Conclusions
Our data suggest that immunohistochemically detectable
expression of PSA and PSAP in male and female breast
carcinomas is infrequent. Thus, PSA and PSAP remain
viable and useful markers for differentiating primary
breast carcinoma from metastatic prostatic carcinoma
Table 4 Previous Reports of Immunohistochemically Detectable PSA Expression in Benign and Malignant Breast
Lesions
Author Number of Cases Antibody, Clone PSA Positive Comments
Carder et al.
2005 [2]
11 MBC Dako, ELY, Cambridgeshire,
UK
1/11 (9%) Focal intense staining
All cases PSAP negative (Dako)
Cheng et al.
2006 [3]
14 MBC Dako, Glostrup, Denmark 0/14 All cases PSAP negative
Ilvan et al.
2004 [10]
109 FBC Dako USA, monoclonal,
prediluted
11/109 (10.1%) All PSA positive cases ER+ PR+
Miller et al.
2001 [11]
75 (74 FBC, 1 MBC) Dako M0750 1:320 7/75 (9%) 5/7 showed weak, focal positivity; MBC
negative
Kidwai et al.
2003 [12]
26 MBC Dako polyclonal 1:1800 6/26 (23%) 5 focally positive
1 diffuse
All PSAP negative
Narita et al.
2006 [13]
156 FBC Dako polyclonal, ready to
use
61/156 (39.1%) Positive correlation with AR expression
Hall et al.
1998 [14]
72 cases Dako, Carpinteria, CA 44/72 (61%)
Alanen et
al. 1999
[15]
171 cases Dakopatts, Glostrup,
Denmark, polyclonal 1:1000
54/171 (31.6%)
Gatalica
et al. 1999
[19]
18 gynecomastia, 8 MBC Rabbit polyclonal, Ventana
Medical Systems, Tucson AZ
5/18 cases of
gynecomastia
(27.8%)
0/8 MBC
Focal strong polyclonal PSA; 4/5 cases
tested with monoclonal PSA and were
negative
All cases PSAP (Ventana PASE/4LT) negative
Quraishi
et al. 2007
[20]
30 (8 DCIS, 19 infiltrating ductal
carcinoma, 3 metastatic breast
carcinoma)
Polyclonal rabbit 0/30
Gupta 1999
[21]
2 MBC Not reported 2/2 (100%) Cell blocks positive; trace PSA positivity in
resection specimens
Tanaka
et al. 2002
[22]
78 FBC Dako A/S Glostrup,
Denmark, polyclonal 1:100
29/78 (32.7%) 6 cases strongly positive
This article 54 FBC
30 MBC
5 gynecomastia
Dako polyclonal 1:10,000 2/54 FBC
1/30 MBC
0/5 gynecomastia
All cases PSAP negative
MBC - male breast carcinoma; FBC - female breast carcinoma; PSA - prostate specific antigen; PSAP - prostate specific acid phosphatase; AR - androgen receptor;
ER - estrogen receptor; PR - progesterone receptor.
Table 3 Grading and Staging Data for PSA-Positive Cases
Age/Sex Nuclear Grade Tumor Size Lymph Node Status Immunohistochemistry
62 F I 1.5 cm Negative (0/18) PSA+ (diffuse), PSAP-,
AR-, ER-, PR-
75 F III 2.5 cm Negative (0/11) PSA+ (focal), PSAP- AR+, ER+, PR+
58 M III 1.3 cm Positive (2/13) PSA+ (focal), PSAP-, AR+, ER+, PR+
PSA - prostate specific antigen; PSAP - prostate specific acid phosphatase; AR - androgen receptor; ER - estrogen receptor; PR - progesterone receptor.
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chemical stain, however, these markers should be used
in conjunction with clinical history, radiology, and histo-
logic findings.
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